Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Sumitomo Pharma Switzerland GmbH
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00579527CT.gov Phase I/II Thymus Transplantation With Immunosuppression #950 | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · DiGeorge Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rabbit Anti-Thymocyte Globulin (this asset) | Sumitomo Pharma Switzerland GmbH | P1/2 | CCC · 52 |
| Melphalan | Paul Szabolcs | P2 | CCC |
| Thiotepa | Washington University School of Medicine | P2 | CCC |
| Alemtuzumab | Paul Szabolcs | P2 | CCC |
| Fludarabine | Paul Szabolcs | P2 | CCC |
| Daclizumab | Sumitomo Pharma Switzerland GmbH | P1/2 | CCC |
| Tacrolimus | Sumitomo Pharma Switzerland GmbH | P1/2 | CCC |
| Cyclosporin A | Sumitomo Pharma Switzerland GmbH | P1/2 | CCC |
| Prednisolone | Sumitomo Pharma Switzerland GmbH | P1/2 | CCC |
Other indications for Rabbit Anti-Thymocyte Globulin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Severe Combined Immunodeficiency | — | P2/3 | B · 61 |
| Bone Marrow Failure Syndrome | — | P2/3 | B · 61 |
| Osteopetrosis | — | P2/3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rabbit Anti-Thymocyte Globulin in DiGeorge Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rabbit-anti-thymocyte-globulin-digeorge-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →